AstraZeneca PLC is hoping to claim a piece of the obesity market, believing its cardiovascular, renal and metabolism (CVRM) strength will be an advantage, despite being well behind rivals. The company announced a licensing deal with Eccogene (Shanghai) Co., Ltd for an oral glucagon-like peptide 1 (GLP-1) receptor agonist for the treatment of obesity, type 2 diabetes and other cardiometabolic conditions on 9 November, coinciding with its third quarter sales and earnings announcement.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?